Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
- PMID: 16009947
- DOI: 10.1200/JCO.2005.14.415
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
Abstract
Purpose: This phase I study was undertaken to define the toxicity, pharmacokinetics, pharmacodynamics, maximum tolerated dose (MTD), and clinical activity of CI-1040, a small-molecule inhibitor of the dual-specificity kinases MEK(mitogen-activated protein kinase kinase) -1 and MEK2 , in patients with advanced malignancy.
Patients and methods: CI-1040 was tested in multiple daily dosing frequencies administered for 21 days repeated every 28 days leading ultimately to continuous administration, and effect of food on absorption was tested. Single dose and steady-state pharmacokinetics were assessed during cycle 1 and phosphorylated extracellular receptor kinase (pERK) levels were assessed in WBCs and also in tumor tissue from selected patients.
Results: Seventy-seven patients received CI-1040 at dose levels ranging from 100 mg QD to 800 mg tid. Grade 3 asthenia was dose limiting at the highest dose level tested, 800 mg tid administered with food. Ninety-eight percent of all drug-related adverse events were grade 1 or 2 in severity; most common toxicities included diarrhea, asthenia, rash, nausea, and vomiting. Plasma concentrations of CI-1040 and its active metabolite, PD 0184264, increased in a less than dose proportional manner from 100 to 800 mg QD. Administration with a high-fat meal resulted in an increase in drug exposure. The MTD and recommended phase II dose was 800 mg BID administered with food. Sixty-six patients were assessable for response. One partial response was achieved in a patient with pancreatic cancer and 19 patients (28%) achieved stable disease lasting a median of 5.5 months (range, 4 to 17 months). Inhibition of tumor pERK (median, 73%; range, 46% to 100%) was demonstrated in 10 patients.
Conclusion: CI-1040 was well tolerated at 800 mg BID administered with food. Both target suppression and antitumor activity were demonstrated in this phase I study.
Similar articles
-
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.Lancet Oncol. 2012 Aug;13(8):773-81. doi: 10.1016/S1470-2045(12)70270-X. Epub 2012 Jul 16. Lancet Oncol. 2012. PMID: 22805291 Clinical Trial.
-
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.J Clin Oncol. 2008 May 1;26(13):2139-46. doi: 10.1200/JCO.2007.14.4956. Epub 2008 Apr 7. J Clin Oncol. 2008. PMID: 18390968 Free PMC article. Clinical Trial.
-
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.Cancer Chemother Pharmacol. 2008 Jun;62(1):97-109. doi: 10.1007/s00280-007-0579-4. Epub 2007 Sep 6. Cancer Chemother Pharmacol. 2008. PMID: 17805538 Clinical Trial.
-
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.J Clin Oncol. 2004 Nov 15;22(22):4456-62. doi: 10.1200/JCO.2004.01.185. Epub 2004 Oct 13. J Clin Oncol. 2004. PMID: 15483017 Clinical Trial.
-
CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).Semin Oncol. 2003 Oct;30(5 Suppl 16):105-16. doi: 10.1053/j.seminoncol.2003.08.012. Semin Oncol. 2003. PMID: 14613031 Review.
Cited by
-
Evolution of Treatment Strategies for Gestational Trophoblastic Neoplasia: Chemotherapy, Immunotherapy, and Molecular Targeted Therapy.Curr Treat Options Oncol. 2024 Aug;25(8):1055-1062. doi: 10.1007/s11864-024-01235-y. Epub 2024 Jul 25. Curr Treat Options Oncol. 2024. PMID: 39052205 Review.
-
Spike-induced cytoarchitectonic changes in epileptic human cortex are reduced via MAP2K inhibition.Brain Commun. 2024 Apr 29;6(3):fcae152. doi: 10.1093/braincomms/fcae152. eCollection 2024. Brain Commun. 2024. PMID: 38741662 Free PMC article.
-
Ocular Toxicity Profile of Targeted Cancer Therapy (TCT) at a US Tertiary Cancer Center.Cureus. 2023 Jun 18;15(6):e40597. doi: 10.7759/cureus.40597. eCollection 2023 Jun. Cureus. 2023. PMID: 37347077 Free PMC article.
-
Embryonic stem cell ERK, AKT, plus STAT3 response dynamics combinatorics are heterogeneous but NANOG state independent.Stem Cell Reports. 2023 Jun 13;18(6):1295-1307. doi: 10.1016/j.stemcr.2023.04.008. Epub 2023 May 18. Stem Cell Reports. 2023. PMID: 37207650 Free PMC article.
-
Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond.Curr Issues Mol Biol. 2023 Feb 27;45(3):1914-1949. doi: 10.3390/cimb45030124. Curr Issues Mol Biol. 2023. PMID: 36975494 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous